Global regulators discuss data requirements for phase 3 trials of COVID-19 vaccines

Regulators focused on requirements for non-clinical and clinical data from early phase studies that are needed before proceeding with advanced trials in humans; e.g. inclusion of diverse populations, primary endpoints and other methodological considerations.


European Medicines Agency